Loading
A phase 2 trial of camrelizumab in colorectal cancer, run by Fudan University, not yet recruiting.
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT06423937 by Fudan University, with a registry enrolment figure of 129 participants, started 2024-05 and due to reach its primary completion in 2026-07. Interventions recorded: combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab. Conditions listed: Colorectal Cancer. Primary outcome: objective response rate (ORR). Colorectal eligibility wording from the registry: "* Patients with histologically or cytologically confirmed non-MSI-H ( according to the detection criteria of the institutional testing center, immunohistochemistry, PCR or NGS detection can be used ) unresectable advanced colorectal cancer with liver metastasis ;". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Camrelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Camrelizumab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/